There are 2789 resources available
Q&A and live discussion
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Invited Discussant 118O and 119O
Presenter: Monica Arnedos
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Monica Arnedos
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Invited Discussant LBA23 and 512O
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
Presenter: Christian Pfister
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
1170O - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)
Presenter: Cécile Le Pechoux
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
Presenter: Nicolas Girard
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast